Save up to 50% on select online and hands-on training bundles!
In this GLP-1 round up:
One of the clearest themes to emerge from February’s research is a reinforcement of something the evidence has been pointing to for years: GLP-1 therapy works best — and lasts longest — when it is delivered as part of a comprehensive, chronic-disease care model rather than as a standalone prescription.
A perspective published in PLOS Medicine by Chao, Gilden, and Wadden notes that GLP-1 and dual-agonist therapies have transformed obesity care, with efficacy that rivals some bariatric procedures in selected trials — as demonstrated in major Phase 3 programs — while the system-level challenges of capacity, monitoring, and access remain significant. The authors highlight the need for oversight, monitoring, and coordinated clinical care rather than casual, stand-alone prescribing of GLP-1s.
This is echoed in a clinical practice discussion on addressing overweight and obesity, which reviews trial-level weight loss of around 15–20% in major Phase 3 trials with current GLP-1 and dual-agonist agents and improvements in sleep apnea, fatty liver disease, and cardiovascular risk markers. The authors stress integrating pharmacotherapy with lifestyle and behavioral interventions and using patient-centered language throughout the care relationship.
Adding urgency to this conversation, BMJ meta-analysis found that GLP-1 treatment discontinuation typically occurs within the first year, and that weight regain after stopping can be more rapid than after dietary interventions alone. This data underscores that the clinical relationship — and the structured support it provides — is what separates durable outcomes from temporary ones.
Action Item: Review your current patient journey from initial consultation through the 12-month mark. Are there structured touchpoints for nutrition, exercise, and adherence support built in? If not, identifying where those gaps exist is a practical first step toward a more integrated model.
February 2026 marked a meaningful expansion in the oral GLP-1 landscape, with new data adding to the momentum that began with the FDA approval of oral Wegovy (semaglutide 25 mg tablets) in late 2025.
A review of Phase 2 and 3 clinical trial data on oral GLP-1 receptor agonists is now informing how clinicians think about positioning these agents relative to injectables in chronic weight management practice. The data suggest that when taken correctly — including fasting requirements for some formulations — oral GLP-1s can achieve meaningful weight loss results.
Adding to the competitive landscape, Kailera Therapeutics and Hengrui Pharma reported positive topline data from a Phase 2 study of oral ribupatide, a GLP-1/GIP dual agonist, showing approximately 12% mean weight loss at 26 weeks compared to 2.3% for placebo. The company simultaneously has an injectable version of ribupatide in a global Phase 3 program enrolling participants across North America, Europe, and other regions, including a head-to-head comparison against semaglutide 2.4 mg, as confirmed by the KaiNETIC Phase 3 program announcement. These head-to-head trials will provide important comparative data for clinical decision-making as the pipeline continues to mature.
Action Item: Consider updating your new patient intake and consultation materials to include a discussion of oral vs. injectable GLP-1 options. A simple comparison of administration requirements, dosing frequency, and current efficacy data can support more informed shared decision-making.
The FDA’s ongoing safety communication on unapproved GLP-1 drugs used for weight loss makes clear that products not evaluated for safety, efficacy, or quality — including compounded versions and those sold for “research use only” — carry serious risks.
A consumer-facing feature in The New York Times added an important clinical dimension to this conversation: patients obtaining GLP-1s through websites, medical spas, or subscription-style telehealth services may find themselves bounced between providers with inconsistent follow-up. Some telehealth models also create structural conflicts of interest when the same company both evaluates patients and sells them medication. Clinicians quoted in the article noted that care that is mostly hands-off risks inappropriate prescribing, insufficient patient support, and slower responses to warning signs.
For providers who have built a structured, relationship-based practice, this is a meaningful distinction — and one worth making explicit with patients who ask about lower-cost alternatives. Consistent monitoring, a known provider relationship, and a care plan that evolves with the patient’s progress are things a subscription platform cannot reliably replicate.
At the same time, several developments in February point toward a future where FDA-approved GLP-1s become more financially accessible. Novo Nordisk announced plans to cut U.S. list prices for Ozempic and Wegovy by up to 50%, effective January 2027.
Separately, the Trump administration announced a deal with Lilly and Novo to provide GLP-1s at most-favored-nation prices — including a cited $245 monthly net price for certain products — applicable to Medicare, Medicaid, and direct-purchase channels. These pricing developments sit alongside the CMS BALANCE model, which opens Medicare Part D and Medicaid coverage for GLP-1s as early as May 2026 when bundled with lifestyle support.
KFF analysis of Medicare Part D data shows rapid GLP-1 spending growth, while a separate KFF brief on Medicaid highlights significant variation in state-level coverage criteria. Longer term, the conversation about generic competition for GLP-1s continues to surface as part of the broader discussion about affordability and access.
Action Item: Designate someone in your practice to monitor coverage and pricing updates on a monthly basis. Resources like GoodRx’s insurance coverage tracker can help your team stay current and provide patients with accurate, up-to-date information on their options.
A large cohort study of 461,382 GLP-1 users found that 12.7% of patients had a new nutritional deficiency diagnosis at just 6 months of therapy. By 12 months, vitamin D deficiency had reached 13.6%. Iron, B vitamins, calcium, selenium, and zinc deficiencies also rose over time. Separate case reports in the same article linked GLP-1 use to severe thiamine deficiency, including cases of Wernicke encephalopathy. The study authors concluded that micronutrient deficiencies during GLP-1 therapy are a common consequence rather than a rare adverse effect, and called for routine nutritional assessment in all long-term users.
Experts presenting at the French Nutrition Days 2025 conference highlighted the risk of sarcopenia and lean mass loss associated with GLP-1-driven weight loss, particularly when weight loss is rapid. The article notes the importance of resistance exercise and adequate protein intake as mitigation strategies, and discusses the need for close monitoring in vulnerable groups. The article also discusses the evolving evidence on GLP-1s and mental health, noting that while some studies have reported reductions in depressive symptoms, data remain limited and careful patient selection is still recommended. The connection between these two issues — nutritional status and muscle preservation — is clinically significant. Patients who are calorically restricted and nutritionally depleted are at greater risk for lean mass loss, making integrated nutritional support not just a quality-of-care issue but a patient safety one.
Action Item: Review your current lab monitoring protocol for GLP-1 patients. If nutritional markers are not already included at baseline and follow-up intervals, consider adding them. A simple patient handout on protein targets and resistance training basics can also be a practical addition to your onboarding materials.
The IAPAM’s Certified Medical Weight Management Provider™ (CWMP) program equips you with the protocols, patient-care strategies, and business tools to implement today’s GLP-1 and metabolic therapies effectively. You’ll learn how to integrate medications like tirzepatide, semaglutide, and Saxenda® into a holistic, sustainable program that prioritizes long-term outcomes.
Stay ahead of the science. Strengthen your systems. Empower your patients to succeed.
Explore the program and get the tools you need to build a sustainable, patient-first weight loss practice.
1. Are oral GLP-1s as effective as injectable versions for weight loss?
Current data suggests oral GLP-1s can achieve meaningful weight loss when taken as directed, including fasting requirements for some formulations. Head-to-head trial data comparing oral and injectable options is still emerging, and the right choice will depend on individual patient factors including adherence patterns, tolerability, and cost.
2. What nutritional deficiencies should I monitor for in GLP-1 patients?
A large cohort study found vitamin D, iron, B vitamins (including thiamine), calcium, selenium, and zinc to be the most commonly affected nutrients. Establishing baseline labs at initiation and repeating them at 6 and 12 months is a reasonable approach based on current evidence.
3. How do I address patients who are using compounded GLP-1s?
The FDA has made clear that compounded GLP-1 products are not evaluated for safety, efficacy, or quality. A non-judgmental, factual conversation about those risks — combined with up-to-date information on available pricing and coverage options for FDA-approved medications — gives patients the information they need to make an informed decision.
4. Will GLP-1 prices actually come down?
Novo Nordisk has announced plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% effective January 2027. Federal pricing agreements and new Medicare and Medicaid coverage models are also in development. The practical impact on individual patient out-of-pocket costs will depend on their insurance plan and the specific coverage decisions of that plan.
5. How can I help patients preserve muscle mass while on GLP-1 therapy?
Current evidence supports resistance exercise and adequate protein intake as the primary strategies for lean mass preservation during GLP-1-driven weight loss. Building specific guidance on both into your patient education materials and care protocols is a practical and evidence-aligned approach.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss.
Sources
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.